advertisement
Abstract #99034 Published in IGR 22-4
Clinical Outcomes of Ahmed ClearPath Implantation in Glaucomatous Eyes: A Novel Valveless Glaucoma Drainage Device
Grover D; Kahook M; Seibold L; Singh IP; Ansari H; Butler M; Smith O; Sawhney G; Van Tassel S; Dorairaj SJournal of Glaucoma 2022; 31: 335-339
PRECIS: DESIGN: ed with novel features to facilitate implantation and improve safety, the Ahmed ClearPath glaucoma drainage device (GDD) provided intraocular pressure reduction comparable to other GDDs in eyes with refractory glaucoma in a multicenter retrospective study. PURPOSE: To present clinical outcomes with a novel valveless glaucoma drainage device (Ahmed ClearPath [ACP], New World Medical). The 250 and 350▒mm2 models feature a contoured plate for optimal globe apposition, anteriorized suture points to facilitate suturing to the globe, and a pre-threaded 4-0 polypropylene ripcord suture. PATIENTS AND METHODS: This was a multicenter retrospective analysis of eyes with medically and/or surgically uncontrolled glaucoma implanted with the 250 or 350▒mm2 ACP either as a standalone procedure or in combination with other procedures. Pre-, intra-, and postoperative data through 6 months were collected. RESULTS: 104 eyes (100 subjects) received the ACP by 10 US surgeons, 63.5% of which had primary open-angle glaucoma and 62.5% had severe glaucoma. Mean baseline IOP was 26.3 (9.0) mmHg and mean medication use was 3.9 (1.3). Through 6 months' follow-up, mean IOP ranged from 13.6-16.7▒mmHg and mean medication use from 0.9-1.9 medications (P<0.0001 at all timepoints for each outcome measure). At 6 months, mean IOP was 13.7▒mmHg (-13.0▒mmHg, 43.0%, P<0.0001) and mean medication use was 1.9 medications per eye (-2.1, 47.7%, P<0.0001). Common adverse events included anterior chamber inflammation (16.3%), hyphema (15.4%), and hypotony (6.7%). CONCLUSION: The new ACP appears to be safe and efficacious as a standalone procedure or in combination with other procedures for uncontrolled glaucoma, and may be considered as a GDD option for patients in whom its unique design may facilitate the implantation process.
Glaucoma Associates of Texas, 10740 N Central Expy #300, Dallas, TX. 75231 University of Colorado School of Medicine. Department of Ophthalmology. Sue Anschutz-Rodgers Eye Center. 1675 Aurora Court, Aurora, CO 80045 University of Colorado School of Medicine. Department of Ophthalmology. Sue Anschutz-Rodgers Eye Center 1675 Aurora Court, Aurora, CO 80045 President- The Eye Centers of Racine and Kenosha 9916 75th St #101, Kenosha, WI 53142; Surgical Instructor- The Chicago Medical School Ophthalmic Consultants of Boston, 50 Staniford Street, #600 Boston, MA Glaucoma Associates of Texas 10740 N Central Expressway #300, Dallas, TX 75231 Glaucoma Associates of Texas Glaucoma Associates of Texas 10740 N Central Expressway #300, Dallas, TX 75231 Georgia Eye Partners, 1100 Johnson Ferry Road, NW, Bldg 1, Suite 108, Atlanta, GA 30342 Weill Cornell Medicine Department of Ophthalmology, 1305 York Ave, New York, NY 10021 Professor of Ophthalmology, Mayo Clinic College of Medicine 4500 San Pablo Road, Jacksonville FL.
Full article